CG Oncology, Inc. (NASDAQ:CGON) is identified as one of the best healthcare stocks with high potential by Guggenheim analyst Brad Canino, who set a $90 price target. The company’s product, cretostimogene, shows promise for treating Non-Muscle Invasive Bladder Cancer (NMIBC), with FDA review expected in 2026. CG Oncology is focused on developing bladder-sparing therapies for bladder cancer, aiming to provide a durable response for patients. While CGON offers investment potential, other AI stocks may have greater upside. Investors can explore opportunities in the AI sector for promising returns.

Read more at Yahoo Finance: CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim